期刊文献+

HCV NS5A抑制剂研究进展 被引量:2

Research progress of HCV NS5A complex inhibitors
原文传递
导出
摘要 近年来抑制丙型肝炎病毒(HCV)复制的直接抗病毒药物得到了快速的发展,HCV非结构蛋白5A(NS5A)抑制剂由于抗病毒活性强、清除病毒快速和抗病毒谱广的特点成为了HCV抑制剂研究的新热点。本文综述了2010年以来有关HCV NS5A抑制剂研究的主要进展,并从化学结构角度出发,对不同化合物的药学特点进行分别阐述和归纳总结。 Direct acting antivirals against the hepatitis C virus (HCV) have been developed and the field has been under a rapid progress in recent years. Especially, HCV inhibitors targeting nonstructural 5A (NS5A) protein are attracting much attention due to the potent antiviral activity, fast viral clearance and broad antiviral spectrum. This article is prepared to cover the main progress of HCV NS5A complex inhibitors in the market since 2010. The pharmaceutical characteristics of diverse compounds are described and summarized according to their different chemotypes.
出处 《药学学报》 CAS CSCD 北大核心 2016年第9期1378-1387,共10页 Acta Pharmaceutica Sinica
基金 北京市自然科学基金资助项目(7132166)
关键词 丙型肝炎病毒 非结构蛋白5A 抑制剂 抗病毒 hepatitis C virus nonstructural 5A protein inhibitor antiviral
  • 相关文献

参考文献55

  • 1http://www, who. Int/mediacentre/factsheets/fs164/en/, 2014.
  • 2Lambert SM, Langley DR, Garnett JA, et al. The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors [J]. Protein Sci, 2014, 23: 723-734.
  • 3Polyak SJ, Khabar KS, Paschal DM, et al. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response [J]. J Virol, 2001, 75: 6095-6106.
  • 4Janardhan SV, Reau NS. Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies? [J]. Hepat Med, 2015: 711-720.
  • 5Liu D, Ji J, Ndongwe TP, et al. Fast hepatitis C virus RNA elimination and NS5A redistribution by NS5A inhibitors studied by a multiplex assay approach [J]. Antimicrob Agents Chemother, 2015, 59: 3482-3492.
  • 6O'Boyle DR 2nd, Nower PT, Lemm JA, et al. Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay [J]. Antimicrob Agents Chemother, 2005, 49: 1346-1353.
  • 7Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect [J]. Nature, 2010, 465: 96-100.
  • 8Belema M, Lopez OD, Bender JA, et al. Discovery and development of hepatitis C virus NS5A replication complex inhibitors [J]. J Med Chem, 2014, 57: 1643-1672.
  • 9Belema M, Nguyen VN, Bachand C, et al. Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir [J]. J Med Chem, 2014, 57: 2013-2032.
  • 10Belema M, Meanwell NA. Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A [J]. J Med Chem, 2014, 57: 5057-5071.

共引文献1

同被引文献23

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部